추천 제품
생물학적 소스
mouse
Quality Level
항체 형태
purified immunoglobulin
항체 생산 유형
primary antibodies
클론
132, monoclonal
종 반응성
human
제조업체/상표
Chemicon®
기술
ELISA: suitable
flow cytometry: suitable
immunofluorescence: suitable
동형
IgG2a
배송 상태
wet ice
일반 설명
Human metapneumovirus (hMPV) is a member of the pneumovirinae subfamily of paramyxoviruses, first described in 2001 from pediatric respiratory specimens in the Netherlands. It is an enveloped pleomorphic virus with a single negative-strand RNA genome. Two major serotypes, A and B, have been described. Several studies identified hMPV in specimens worldwide, and estimated that by age 5 years 70% of children have developed antibodies to hMPV.
애플리케이션
Anti-Human Metapneumovirus Antibody, clone 132 is an antibody against Human Metapneumovirus for use in ELISA, FC & IF.
물리적 형태
Format: Purified
기타 정보
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
법적 정보
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our 제품 선택기 도구.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Nature communications, 13(1), 2546-2546 (2022-05-11)
Human metapneumovirus (hMPV) belongs to the Pneumoviridae family and is closely related to respiratory syncytial virus (RSV). The surface fusion (F) glycoprotein mediates viral fusion and is the primary target of neutralizing antibodies against hMPV. Here we report 113 hMPV-F
Journal of virology, 97(12), e0105223-e0105223 (2023-11-30)
Human metapneumovirus (hMPV) is a common pathogen causing lower respiratory tract infections worldwide and can develop severe symptoms in high-risk populations such as infants, the elderly, and immunocompromised patients. There are no approved hMPV vaccines or neutralizing antibodies available for
Nature communications, 10(1), 4153-4153 (2019-09-14)
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation
Virology, 509, 60-66 (2017-06-13)
Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production
mAbs, 11(8), 1415-1427 (2019-08-14)
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children and older adults. Currently, no licensed vaccine is available, and therapeutic options are limited. The primary target of neutralizing antibodies to RSV is the
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.